8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)  May 26, 2005

                       NEW BRUNSWICK SCIENTIFIC CO., INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         New Jersey                       0-6994                  22-1630072
- ----------------------------           ------------          -------------------
(State or other jurisdiction           (Commission             (I.R.S. Employer
     of incorporation)                 File Number)          Identification No.)

          44 Talmadge Road, Edison NJ                            08818-4005
    ----------------------------------------                     ----------
    (Address of principal executive offices)                     (Zip Code)


Registrant's telephone number, including area code  732.287.1200


         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 8.01   OTHER EVENTS

On May 27, 2005, NEW BRUNSWICK SCIENTIFIC CO., INC., issued a press release
entitled "New Brunswick Scientific to Introduce Five Innovative New Products at
the American Society for Microbiology (ASM) General Meeting" attached here.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS

     (c)    EXHIBITS

  99.1      Press release dated May 27, 2005.



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                              NEW BRUNSWICK SCIENTIFIC CO., INC.
                                              ----------------------------------
                                              (Registrant)

Date May 27, 2005

                                              /s/ Samuel Eichenbaum
                                              ----------------------------------
                                              Samuel Eichenbaum
                                              Vice President, Finance

EX-99.1

                                                                    Exhibit 99.1

      NEW BRUNSWICK SCIENTIFIC TO INTRODUCE FIVE INNOVATIVE NEW PRODUCTS AT
           THE AMERICAN SOCIETY FOR MICROBIOLOGY (ASM) GENERAL MEETING

EDISON, N.J., May 27 /PRNewswire-FirstCall/ -- New Brunswick Scientific Co.,
Inc. (NBS) (Nasdaq: NBSC), yesterday announced that it will be introducing five
innovative new products at the American Society for Microbiology (ASM) General
Meeting, which opens on June 6th in Atlanta, GA. The announcement by James
Orcutt, NBS President and COO, was made during an open question and answer forum
at the Company's annual shareholders' meeting.

The products were identified as two new biological shakers, Innova(R) 40, a
benchtop incubated and refrigerated system; and Innova 43, a larger-scale floor
model. Innova shakers are the workhorses of the industry, known for precision
control of operating parameters and exceptionally long life. With this latest
complement to its shaker family, the Company now offers over 30 shaker models --
the largest selection offered by any manufacturer -- providing life scientists
with a range of options to suit virtually any culture requirement.

A new slim upright, 360 liter capacity, ultra-low temperature freezer, Innova
U360, will also be introduced. This latest freezer in the Innova family utilizes
vacuum-insulation panel technology in place of traditional insulating foam.
Vacuum-insulation panels reduce wall thickness, thereby maintaining a small
footprint while increasing interior storage capacity. With the addition of the
Innova U360, the Company now offers ten freezer models, including a unique
personal-sized unit for on- or under-bench use.

Mr. Orcutt also announced plans to introduce a new 500 mL disposable cell
culture system. FibraStage(TM), the first truly disposable product in NBS'
product range, offers the simplicity of operation and convenience of disposable
technology, while providing higher yields than typically achieved using
traditional culture systems, such as spinners, T-flasks and roller bottles. He
went on to explain that the Company's proprietary FibraCel(R) disks, which are
at the heart of the FibraStage system, are currently being used to produce the
world's first licensed gene therapy drug.

Rounding out the new product introductions is the NucleoCounter YC-100, a device
for more accurately and automatically counting yeast cells. The YC-100 serves as
a counterpoint to the original NucleoCounter, which automates the tedious task
of counting mammalian cells. Mr. Orcutt commented that "accelerated and targeted
new product development is among several strategic initiatives upon which NBS is
focused. With the introduction of these products at ASM, the results of this
sustained effort are beginning to show."

To be added to New Brunswick Scientific's e-mail distribution list,
please click on the link below:

http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html



About New Brunswick Scientific

New Brunswick Scientific Co., Inc., is a leading global provider of a
comprehensive line of research equipment and scientific instrumentation for use
in the life science industry. The Company's products are used in the creation,
maintenance and control of physical and biochemical environments required for
the growth, detection and storage of microorganisms for medical, biological and
chemical applications, as well as environmental research and commercial product
development. NBS is a forerunner in the research and development of pioneering
equipment to meet the challenges of new areas of advancement in life science.
Established in 1946, New Brunswick Scientific is headquartered in Edison, New
Jersey, with sales and distribution facilities strategically located in the
United States, Europe and Asia. For more information, please visit
http://www.nbsc.com .

This document contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements may
be identified by words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "will" or words of similar meaning and
include, but are not limited to, statements about the expected future business
and financial performance of the Company. The forward-looking statements involve
a number of risks and uncertainties, including but not limited to, changes in
economic conditions, demand for the Company's products, pricing pressures,
intense competition in the industries in which the Company operates, the need
for the Company to keep pace with technological developments and respond in a
timely manner to changes in customer needs, the Company's dependence on
third-party suppliers, the effect on foreign sales of currency fluctuations,
acceptance of new products, the labor relations of the Company and its customers
and other factors identified in the Company's Securities and Exchange Commission
filings. Forward-looking statements are based on management's current
expectations and assumptions, which are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict. Actual
outcomes and results may differ materially from these expectations and
assumptions due to changes in global political, economic, business, competitive,
market, regulatory and other factors. The Company undertakes no obligation to
publicly update or review any forward-looking information, whether as a result
of new information, future developments or otherwise.

SOURCE  New Brunswick Scientific Co., Inc.
    -0-                             05/27/2005
    /CONTACT:  Samuel Eichenbaum, Vice President, Finance and Treasurer,
New Brunswick Scientific Co., Inc., +1-732-650-2500, same@nbsc.com; Matthew J.
Dennis, CFA, NBS Investor Relations, Clear Perspective Group, LLC,
+1-440-353-0552, mdennis@cpg-llc.com, for New Brunswick Scientific Co., Inc./
    /Web site:  http://www.nbsc.com /